• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癫痫患者的苯妥英钠剂量调整。

Phenytoin dose adjustment in epileptic patients.

机构信息

Department of Pharmacology, Material Medica and Therapeutics, University of Manchester.

出版信息

Br J Clin Pharmacol. 1974 Apr;1(2):163-8. doi: 10.1111/j.1365-2125.1974.tb00226.x.

DOI:10.1111/j.1365-2125.1974.tb00226.x
PMID:22454904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1402441/
Abstract

1 A preliminary survey showed that many outpatients with partially controlled epilepsy had serum concentrations of phenytoin below the recommended therapeutic range (10-20 μg/ml). A phenytoin tolerance test was devised with the intention of predicting a more adequate daily dose for such a patient. 2 Fifteen patients were each given an oral test dose of 600 mg phenytoin sodium and the serum concentration of phenytoin was measured at intervals over 48 h; the concentration rose during the first 4 h and decayed between 12-48 h as an almost linear function of time. 3 The serum concentration/time curves were fitted by an interative computer program based on the Michaelis-Menten equation. The mean saturated rate of elimination of phenytoin was 435 mg/day and the serum concentration (K(m)) corresponding with 50% saturation was 3.8 μg/ml. The mean calculated dose of phenytoin sodium required for a steady state serum concentration of 10-20 μg/ml was 345-400 mg/day. 4 The Michaelis-Menten principle was used to predict steady state serum phenytoin concentrations in individual patients receiving daily doses of phenytoin sodium adjusted by steps of 100 mg. The serum concentrations tended to be either too low or too high. The steep relationship between phenytoin concentration and dose indicates that when the concentration reaches 5-10 μg/ml it is then appropriate to adjust dose by small steps of about 25 mg.

摘要
  1. 初步调查显示,许多部分控制的癫痫患者的血清苯妥英钠浓度低于推荐的治疗范围(10-20μg/ml)。设计了苯妥英钠耐受试验,旨在预测此类患者更合适的日剂量。

  2. 15 名患者每人给予 600mg 苯妥英钠钠的口服试验剂量,并在 48 小时内每隔一段时间测量血清苯妥英钠浓度;浓度在前 4 小时内上升,在 12-48 小时之间以时间的几乎线性函数下降。

  3. 血清浓度/时间曲线通过基于米氏方程的迭代计算机程序拟合。苯妥英钠的平均饱和消除率为 435mg/天,对应 50%饱和的血清浓度(K(m))为 3.8μg/ml。达到 10-20μg/ml 稳态血清浓度所需的苯妥英钠钠的平均计算剂量为 345-400mg/天。

  4. 米氏原理用于预测每天接受苯妥英钠钠剂量调整 100mg 步长的个体患者的稳态血清苯妥英浓度。血清浓度往往过低或过高。苯妥英钠浓度与剂量之间的陡峭关系表明,当浓度达到 5-10μg/ml 时,通过约 25mg 的小步调整剂量是合适的。

相似文献

1
Phenytoin dose adjustment in epileptic patients.癫痫患者的苯妥英钠剂量调整。
Br J Clin Pharmacol. 1974 Apr;1(2):163-8. doi: 10.1111/j.1365-2125.1974.tb00226.x.
2
Phenytoin pharmacokinetic analysis and steady-state level prediction using a programmable calculator.
Int J Biomed Comput. 1980 Jul;11(4):329-034. doi: 10.1016/0020-7101(80)90036-7.
3
Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients.
Int J Clin Pharmacol Ther Toxicol. 1989 Apr;27(4):173-8.
4
Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
Ther Drug Monit. 1984;6(1):11-4.
5
Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
Ther Drug Monit. 1985;7(4):405-10. doi: 10.1097/00007691-198512000-00007.
6
Phenytoin age-dose-concentration relationship in children.
Ther Drug Monit. 1994 Apr;16(2):145-50. doi: 10.1097/00007691-199404000-00006.
7
Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.代谢物生成动力学建模的经典米氏方程和系统理论方法
Eur J Drug Metab Pharmacokinet. 2004 Jul-Sep;29(3):205-14. doi: 10.1007/BF03190599.
8
Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrations.使用非稳态苯妥英浓度评估贝叶斯回归分析计算机程序
Clin Pharm. 1987 Aug;6(8):634-9.
9
Individualization of phenytoin dosage regimens.
Clin Pharmacol Ther. 1977 Mar;21(3):287-93. doi: 10.1002/cpt1977213287.
10
Optimization of phenytoin therapy in adults with epilepsy in the Western Cape, South Africa.
J Clin Pharm Ther. 1999 Oct;24(5):381-5. doi: 10.1046/j.1365-2710.1999.00241.x.

引用本文的文献

1
Fabrication of Bio-Nanocomposite Based on HNT-Methionine for Controlled Release of Phenytoin.基于埃洛石纳米管-蛋氨酸的生物纳米复合材料的制备用于苯妥英的控释
Polymers (Basel). 2021 Aug 3;13(15):2576. doi: 10.3390/polym13152576.
2
Differential kinetics of phenytoin in elderly patients.老年患者苯妥英钠的差异动力学
Drugs Aging. 1999 Sep;15(3):235-50. doi: 10.2165/00002512-199915030-00006.
3
Hospital prescribing of phenytoin for epilepsy.医院针对癫痫开具苯妥英的处方情况。
J R Coll Physicians Lond. 1981 Jan;15(1):41-4.
4
Rapid and slow release phenytoin in epileptic patients at steady state: assessment of relative bioavailability utilizing Michaelis-Menten parameters.
J Pharmacokinet Biopharm. 1982 Aug;10(4):383-91. doi: 10.1007/BF01065170.
5
Anticonvulsant drugs. An update.抗惊厥药物。最新进展。
Drugs. 1984 Apr;27(4):328-63. doi: 10.2165/00003495-198427040-00003.
6
Comparison of drug dosing methods.药物给药方法的比较。
Clin Pharmacokinet. 1985 Jan-Feb;10(1):1-37. doi: 10.2165/00003088-198510010-00001.
7
Phenytoin dosage predictions in paediatric patients.小儿患者苯妥英钠的剂量预测
Clin Pharmacokinet. 1989 Apr;16(4):254-60. doi: 10.2165/00003088-198916040-00004.
8
Nonlinear pharmacokinetics: clinical Implications.非线性药代动力学:临床意义。
Clin Pharmacokinet. 1991 Jun;20(6):429-46. doi: 10.2165/00003088-199120060-00001.
9
Nonlinear assessment of phenytoin bioavailability.苯妥英生物利用度的非线性评估。
J Pharmacokinet Biopharm. 1976 Aug;4(4):327-36. doi: 10.1007/BF01063122.
10
Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.唾液苯妥英放射免疫测定法。一种评估非蛋白结合药物浓度的简单方法。
Eur J Clin Pharmacol. 1977;11(1):71-4. doi: 10.1007/BF00561791.

本文引用的文献

1
Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration.静脉注射后苯妥英在正常人体中的代谢情况。
Clin Pharmacol Ther. 1969 Jul-Aug;10(4):498-504. doi: 10.1002/cpt1969104498.
2
Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.苯妥英钠治疗癫痫。问题患者的剂量调整。
JAMA. 1968 Mar 11;203(11):969-72.
3
Microdetermination of diphenylhydantoin in biological specimens by ultraviolet spectrophotometry.用紫外分光光度法微量测定生物样品中的二苯乙内酰脲。
Anal Chem. 1968 May;40(6):978-80. doi: 10.1021/ac60262a023.
4
Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.通过拟合米氏方程的积分形式来解释苯妥英血浆水平的剂量依赖性下降。
Res Commun Chem Pathol Pharmacol. 1972 May;3(3):455-66.
5
Effect of dosage increments on blood phenytoin concentrations.剂量增加对血液中苯妥英浓度的影响。
J Neurol Neurosurg Psychiatry. 1972 Dec;35(6):873-6. doi: 10.1136/jnnp.35.6.873.
6
Pharmacokinetic study of a patient with diphenylhydantoin toxicity.苯妥英钠中毒患者的药代动力学研究。
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):521-8. doi: 10.1002/cpt1973144part1521.